SEC Form 4 · accession 0001144204-15-042554
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Pruzanski
Officer — CEO & President · Director
Period of report
Jul 10, 2015
Accepted (ET)
Jul 14, 2015 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 10, 2015 | M | 12,500 | $8.6667 | A | 519,514 | D | |
| Common Stock | Jul 10, 2015 | S | 12,500 | $250.00 | D | 507,014 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2 | $8.6667 | Jul 10, 2015 | M | 12,500 | D | — | Aug 16, 2020 | Common Stock | 12,500 | 116,628 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 27, 2015.
- F2All shares underlying this option have vested.